Where does Ansbert K. Gadicke work?

Ansbert K. Gadicke is Managing Partner at MPM BioImpact and Board director at Reunion Neuroscience and Board director at iTeos Therapeutics and Board director at ViraCyte.

What boards does Ansbert K. Gadicke sit on?

Ansbert K. Gadicke holds tracked board seats at Chiasma, Clinical ink, iTeos Therapeutics, NextPoint Therapeutics, Orna Therapeutics Holdings, LLC, Reunion Neuroscience, ViraCyte.

Ansbert K. Gadicke

Investor

Managing Partner at MPM BioImpact · Board director at Reunion Neuroscience · Board director at iTeos Therapeutics · Board director at ViraCyte

Boston, Massachusetts

About

Managing Partner and founder of MPM Capital in 1992 as a biotech venture capital firm. Led investments in major successes including BioMarin Pharmaceuticals, Pharmasset (acquired by Gilead), and Cullinan Therapeutics. Recipient of 2017 Global Oncology Visionary Award.

Contact· self-published, not guessed

a•••@mpmcapital.comreveal

Board director at Reunion Neuroscience

Intro paths

→

In turn, Ansbert can intro founders to Reunion Neuroscience's investors below.

Reunion Neuroscience's investors · 4

FemHealth VenturesShort Hills Mitsui Global InvestmentMenlo Park · $500K – $10M checks MPM BioImpactBoston · $1M – $15M checks · since 2025 Novo HoldingsCopenhagen · $1.1M – $54M checks · since 2025

Board director at iTeos Therapeutics

Intro paths

→

In turn, Ansbert can intro founders to iTeos Therapeutics's investors below.

iTeos Therapeutics's investors · 2

MPM BioImpactBoston · $1M – $15M checks · since 2020 VIVES PartnersWavre · $108K – $7.6M checks · since 2020

Co-founders at iTeos Therapeutics

Michel DetheuxExecutive Officer, Director

Board director at ViraCyte

Intro paths

→

In turn, Ansbert can intro founders to ViraCyte's investors below.

ViraCyte's investors · 1

MPM BioImpactBoston · $1M – $15M checks · since 2018

Co-founders at ViraCyte

Juan VeraDirector

Malcom BrennerDirector

Experience

MPM BioImpactManaging Partnercurrent1992 — present

Deals · 5

Reunion NeuroscienceBoard seat

via MPM BioImpact · filed Sep 2025 · $119.8M raise

Orna Therapeutics Holdings, LLCBoard seat

via MPM BioImpact · filed Aug 2022

iTeos TherapeuticsBoard seat

via MPM BioImpact · filed Mar 2020

ViraCyteBoard seat

via MPM BioImpact · filed Sep 2018

ChiasmaBoard seat

via MPM BioImpact · filed Mar 2015 · $87.2M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Clinical ink NextPoint Therapeutics

Per SEC Form D filings.

Colleagues at MPM BioImpact

Alim Ladha

Senior Associate at MPM Capital

Andrew Scharenberg

Entrepreneur Partner at MPM BioImpact

Ansbert Gadicke, M.D.

Chairman at MPM BioImpact

Aparna Parikh

Entrepreneur Partner at MPM BioImpact

Bard Geesaman

Managing Partner at MPM Capital

Binsen Li

Principal at MPM BioImpact

Brendan Furey

Chief Compliance Officer at MPM BioImpact

Brian Goodman

Partner at MPM BioImpact

Network9

Alim Ladha

Senior Associate at MPM Capital

Briggs Morrison

Entrepreneur Partner at MPM BioImpact

Dan Hicklin

Managing Partner at MPM Capital

David Kolesky

Principal at MPM BioImpact

David Stack

Managing Partner at MPM Capital

Detlev Biniszkiewicz

Managing Director at MPM BioImpact

Devin Quinlan

Principal at MPM BioImpact

Ed Hurwitz

Managing Director at MPM Capital

Geraldine Paulus

Senior Associate at MPM Capital

Investors connected to Ansbert in public investor directories — a warm-intro map.

Frequently asked questions

Who is Ansbert K. Gadicke?: Managing Partner and founder of MPM Capital in 1992 as a biotech venture capital firm. Led investments in major successes including BioMarin Pharmaceuticals, Pharmasset (acquired by Gilead), and Cullinan Therapeutics. Recipient of 2017 Global Oncology Visionary Award.
Where does Ansbert K. Gadicke work?: Ansbert K. Gadicke is Managing Partner at MPM BioImpact and Board director at Reunion Neuroscience and Board director at iTeos Therapeutics and Board director at ViraCyte.
What boards does Ansbert K. Gadicke sit on?: Ansbert K. Gadicke holds tracked board seats at Chiasma, Clinical ink, iTeos Therapeutics, NextPoint Therapeutics, Orna Therapeutics Holdings, LLC, Reunion Neuroscience, ViraCyte.